Cancer breakthroughs add pressure to control costs
(Reuters) - An exciting class of new cancer drugs may boost patients' odds for survival, but healthcare providers and insurers will be under pressure to find savings elsewhere to pay for the high price tags of the new treatments. Doctors at this week's annual meeting of the American Society of Clinical Oncology heard groundbreaking data on a new class of immune system boosters that some believe will become the main treatment for more than half of all cancers in the next 10 years. They included drugs from Bristol-Myers Squibb and Merck & Co that shrank tumors in patients with advanced melanoma and lung cancer.
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- EHR Systems 'Immature, Costly,' AMA Says
- Data Points to Boom in Private HIX
- Few Winners Among MSSP Participants
- Technology Lights Up Health Innovation Forum
- Interstate Medical Licensure Effort Advances
- How to Build a Health Plan from Scratch
- Better HCAHPS Scores Protect Revenue
- Malnourishment 'Epidemic' Plagues Hospitals? Really?
- Hospitals and doctors fail patients by passing the buck on insurance rules